A 28-year-old woman from Mumbai presents with secondary amenorrhea for 8 months. She has a history of dilation and curettage (D&C) 1 year ago for termination of pregnancy. On examination, she has normal secondary sexual characteristics and normal external genitalia. Serum FSH, LH, estradiol, and prolactin are all normal. Pelvic ultrasound shows a thin endometrium (< 4 mm) with a normal uterine cavity outline. What is the most appropriate next step in management?

Explanation

## Clinical Diagnosis: Asherman Syndrome This patient presents with **secondary amenorrhea** with a highly suggestive history: - **Risk factor:** D&C 1 year ago (most common cause of Asherman syndrome) - **Normal hormonal profile** → normal HPO axis - **Thin endometrium (< 4 mm)** on ultrasound → endometrial damage/scarring - **Normal uterine cavity outline** → no structural distortion initially This clinical picture is **pathognomonic for Asherman syndrome** (intrauterine adhesions). ## Why Hysteroscopy is the Next Step **Key Point:** Hysteroscopy is both diagnostic AND therapeutic in Asherman syndrome. It is the gold standard investigation and treatment. ### Diagnostic Value - **Direct visualization** of intrauterine adhesions (bands of scar tissue) - **Assessment of severity** — partial vs. complete obliteration of uterine cavity - **Identification of location** — fundal, lateral, or involving the cervix - **Grading** — mild, moderate, or severe (Scaramuzza classification) ### Therapeutic Value - **Lysis of adhesions** — mechanical or electrosurgical division of scar bands - **Restoration of normal uterine cavity** — allows endometrial regeneration - **Improved fertility outcomes** — particularly important in reproductive-age women **Clinical Pearl:** Asherman syndrome is one of the few causes of secondary amenorrhea where the diagnosis and treatment can be accomplished in a single procedure. **High-Yield:** Thin endometrium (< 4 mm) on ultrasound in the setting of a history of uterine instrumentation (D&C, curettage, myomectomy) is a red flag for Asherman syndrome and mandates hysteroscopy. ## Asherman Syndrome: Pathophysiology ```mermaid flowchart TD A[Uterine Instrumentation<br/>D&C, curettage, myomectomy]:::action --> B[Damage to Basal Layer<br/>of Endometrium] B --> C[Abnormal Wound Healing] C --> D[Formation of Fibrous Adhesions<br/>Intrauterine Synechiae] D --> E[Partial or Complete<br/>Obliteration of Cavity] E --> F[Amenorrhea or Hypomenorrhea] F --> G[Hysteroscopy + Lysis]:::action G --> H[Restoration of Cavity<br/>Endometrial Regeneration]:::outcome ``` ## Why Other Options Are Incorrect **Progestin challenge test:** While useful in primary amenorrhea or when outflow obstruction is suspected, it is not indicated here. The diagnosis is already clear from the clinical context and imaging. A positive response (withdrawal bleeding) would not change management, as hysteroscopy is still needed for definitive diagnosis and treatment. **Hormone replacement therapy:** Not indicated as first-line management. HRT may be considered after hysteroscopy if endometrial regeneration fails, but it does not address the underlying anatomical problem. **Transvaginal ultrasound with saline infusion:** While this can provide additional detail about the cavity, it is inferior to hysteroscopy for both diagnosis and treatment. Hysteroscopy allows direct visualization and simultaneous therapeutic intervention. [cite:Padubidri & Daftary's Obstetrics and Gynaecology for NEET PG Ch 9; FIGO Classification of Intrauterine Adhesions]